DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Navigator Guided e-Psychoeducational Intervention

Completed

Conditions: Prostate Cancer

Interventions: Other: Personalized Health Information Navigator (PHIN)
Other: NCI Information Booklets (IB)

First Posted Date: 2014-07-10

Last Posted Date: 2017-08-22

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 391

Registration Number: NCT02186444

Locations: 🇺🇸
H. Lee Moffitt Cancer and Research Institute, Tampa, Florida, United States

Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Cisplatin
Radiation: Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2014-06-06

Last Posted Date: 2023-01-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT02158234

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Smoking Cessation for Cervical Cancer Survivors

Not Applicable

Completed

Conditions: Smoking Cessation
Cervical Cancer
Tobacco Use

Interventions: Behavioral: Self-Help Materials
Drug: Nicotine Patch
Behavioral: REDCap
Procedure: Saliva Test
Drug: Nicotine lozenge
Behavioral: Telephone Counseling Sessions

First Posted Date: 2014-06-06

Last Posted Date: 2023-07-20

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 202

Registration Number: NCT02157610

Locations: 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: BYL719
Drug: Gemcitabine
Drug: (nab)-paclitaxel

First Posted Date: 2014-06-04

Last Posted Date: 2021-04-08

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 15

Registration Number: NCT02155088

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2014-05-15

Last Posted Date: 2021-02-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 15

Registration Number: NCT02139358

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Enzalutamide
Drug: Gemcitabine
Drug: Nab-paclitaxel

First Posted Date: 2014-05-14

Last Posted Date: 2021-08-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 25

Registration Number: NCT02138383

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

Phase 2

Completed

Conditions: Cancer of the Bile Duct

Interventions: Drug: Regorafenib

First Posted Date: 2014-04-16

Last Posted Date: 2021-10-12

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 39

Registration Number: NCT02115542

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
VCU Massey Cancer Center, Richmond, Virginia, United States

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: HER-2 pulsed Dendritic Cell Vaccine

First Posted Date: 2014-02-14

Last Posted Date: 2025-04-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 15

Registration Number: NCT02063724

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Biomarker Correlates of Hypoxia in Metastatic Melanoma

Phase 2

Withdrawn

Conditions: Melanoma
Skin Cancer

Interventions: Drug: Pimonidazole hydrochloride (Hypoxyprobe™-1)
Drug: Optional 18F-FMISO PET scan (18F-fluoromisonidazole)
Procedure: Surgical Resection of Melanoma Metastases

First Posted Date: 2014-02-12

Last Posted Date: 2016-05-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT02061007

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: HER-2 pulsed Dendritic Cell Vaccine

First Posted Date: 2014-02-12

Last Posted Date: 2024-08-02

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 7

Registration Number: NCT02061423

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy